Nestle announces vitamins business review after sluggish sales growth
Shares in Nestle, the world's biggest food producer, fell to a six-month low in early market trade and were 4.7% lower by 0950 GMT.
As the economic downturn globally has squeezed customers and driven them to cheaper alternatives, the Swiss-based maker of KitKat chocolate bars, Nespresso coffee and Maggi seasoning has found it harder to sell its branded projects.
Thursday's results add to investor pressure on CEO Laurent Freixe to revive the company's share price and sales. Since his appointment in August last year, Nestle's share price has lagged rivals, including Unilever and Danone.
The Swiss company on Thursday maintained its 2025 outlook, saying it expects organic sales growth to improve. It estimated an underlying trading operating profit margin at or above 16%, including the negative impact from tariffs and current FX rates.
Nestle's Vitamins, Minerals and Supplements business generates around 1 billion Swiss francs (US$1.26 billion) in annual sales, Nestle said.
VMS is part of Nestle's wider Nutrition and Health Science division, which accounted for a little more than 16% of group sales in the first half and recorded a decline in real internal growth - or sales volumes - of 0.8%.
'We have launched a strategic review of our underperforming mainstream and value brands, including Nature's Bounty, Osteo Bi-Flex, Puritan's Pride, and U.S. private label, which may result in the divestment of these brands,' Nestle said.
Freixe said Nestle would focus on its global premium VMS brands and that a potential divestment of the others could happen in 2026.
'To us, the highest potential is at the premium end,' Freixe told reporters.
Growth disappoints
Nestle said that first-half organic sales growth, which excludes the impact of currency movements and acquisitions, rose 2.9% in the six months through June, just above the average of analysts' forecasts of 2.8%.
But real internal growth, or RIG, was 0.2%, below the consensus forecast of 0.4%, reflecting softer demand as customers balk at price increases.
Total reported sales decreased by 1.8% to 44.2 billion Swiss francs, compared to analyst expectations of 44.6 billion francs, a drop Nestle attributed in part to the negative impact of 4.7% from foreign exchange as the Swiss franc has strengthened this year.
Nestle's 2.7% price increases were above the average analyst estimate of 2.5%.
'The headline will be the negative RIG of -0.3% in Q2 when most investors were positioned for a positive number,' Barclays analysts said in a note. 'This will be seen as a bit disappointing.'
Despite the 'negative surprise' in Nestle's Health Science unit, Vontobel analysts said the overall results would likely reassure investors that Nestle is on the long road to recovery.
Reporting by Alexander Marrow and Oliver Hirt; editing by Barbara Lewis, Reuters
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
CRH plc Updates on Voting Rights and Capital Structure
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. CRH plc ( (CRH)) has issued an update. CRH plc announced that as of July 31, 2025, it has 710,726,418 Ordinary Shares in issue, with 38,314,040 held as Treasury Shares, resulting in a total of 672,412,378 voting rights. This information is crucial for shareholders to determine their notification requirements under the UK's Financial Conduct Authority's rules, impacting their interest calculations in the company. More about CRH plc CRH plc is a leading company in the building materials industry, providing a wide range of products and services to the construction sector. The company focuses on delivering innovative solutions and maintaining a strong market presence globally. For an in-depth examination of CRH stock, go to TipRanks' Overview page.
CTV News
2 hours ago
- CTV News
Colgate-Palmolive beats quarterly estimates on steady demand for essentials
Colgate-Palmolive beat first-quarter sales and profit estimates on Friday, as resilient demand for its essentials such as oral and personal care products overcame rising prices and tariff uncertainties. (solidcolours / Colgate-Palmolive beat first-quarter sales and profit estimates on Friday, as resilient demand for its essentials such as oral and personal care products overcame rising prices and tariff uncertainties. Why it's important Colgate-Palmolive joined peers such as Procter & Gamble and Kimberly-Clark in posting upbeat sales growth, unlike the broader retail sector that has been struggling with a slowdown in discretionary spending. U.S. President Donald Trump administration's shifting trade policies have forced several companies to hike prices, pushing shoppers to focus on essentials. Context Colgate has raised prices over the past few quarters to counter tariff impacts and higher advertising and marketing costs. The marketing campaigns have helped increase the sales. The company, which makes U.S. toothpaste in Mexico, now expects incremental costs from tariffs to be about US$75 million, lower than $200 million projected earlier, as it expects more favorable rates. It also outlined a five-year cost cutting plan. By the numbers Sales rose eight per cent in Africa and 7.8 per cent in Europe from a year ago. The company expects organic sales growth to be at the low end of its forecast range of two to four per cent. Its prices rose two per cent in the quarter ended June 30 and total organic volumes slipped 0.2 per cent, compared with a year ago. Colgate-Palmolive's adjusted profit of 92 cents per share in the first quarter topped analysts' estimates of 90 cents per share, according to data compiled by LSEG. It posted quarterly net sales of $5.11 billion, beating estimates of $5.03 billion. Market reaction Shares of the company were flat in premarket trading. (Reporting by Anuja Bharat Mistry in Bengaluru; Editing by Sahal Muhammed)
CTV News
4 hours ago
- CTV News
Novo Nordisk shares extend losses, erasing nearly all gains since Wegovy launch
The weight-loss drug Wegovy is shown in this undated photo. THE CANADIAN PRESS/handout, Novo Nordisk Canada Inc. Shares in Novo Nordisk fell as much as six per cent on Friday to their lowest since August 2021, extending recent losses to wipe out almost all the gains made since the drugmaker launched its blockbuster weight-loss treatment Wegovy. The fall comes after U.S. President Donald Trump on Thursday sent letters to 17 major pharmaceutical firms, including Novo Nordisk, telling them to cut drug prices in the United States. That prompted share price declines across the sector. Novo Nordisk on Tuesday slashed its forecast for 2025 sales growth due to competition from compounded, or copycat, versions of Wegovy and appointed veteran insider Maziar Mike Doustdar as its new CEO, prompting its shares to fall 23 per cent on the day. Novo became Europe's most valuable listed company following the launch of Wegovy in June 2021. But its shares have plunged by more than two-thirds since peaking last year on concerns the drugmaker is losing ground in the obesity drug race. 'The U.S. healthcare system is complex, but Novo Nordisk will continue to work to find solutions that help people access the medicines they need at affordable prices,' Novo said in an emailed statement. Novo's shares were 4.9 per cent lower at 08:39 GMT. Friday's drop brings this week's losses to more than 30 per cent - the stock's worst-ever weekly fall. The European healthcare index .SXDP was down 1.6 per cent, its lowest since April. 'Trump doesn't have the mandate to tell Novo Nordisk how to price their products in the U.S., but investors are just panicking about the risk of another downgrade,' said Nordnet analyst Per Hansen. The pressure to lower prices adds to Novo's problems in the United States, its biggest market. It faces competition from Eli Lilly LLY.N and from compounders - custom-made medicines that are based on the same ingredients as branded drugs. 'This is a repricing of the obesity market, it's a repricing of the United States as the world's most attractive drug market, and it's a repricing of the risk from Donald Trump,' Hansen said. (Reporting by Anna Pruchnicka, Elviira Luoma, Jacob Gronholt-Pedersen and Louise Breusch Rasmussen. Editing by Amanda Cooper and Mark Potter)
